Koss Olinger Consulting LLC Increases Holdings in Eli Lilly and Company $LLY

Koss Olinger Consulting LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 498 shares of the company’s stock after buying an additional 28 shares during the quarter. Koss Olinger Consulting LLC’s holdings in Eli Lilly and Company were worth $388,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Schmidt P J Investment Management Inc. lifted its position in Eli Lilly and Company by 2.5% during the second quarter. Schmidt P J Investment Management Inc. now owns 19,764 shares of the company’s stock worth $15,406,000 after buying an additional 482 shares in the last quarter. Brookwood Investment Group LLC lifted its position in Eli Lilly and Company by 57.1% during the second quarter. Brookwood Investment Group LLC now owns 4,261 shares of the company’s stock worth $3,322,000 after buying an additional 1,549 shares in the last quarter. GoalVest Advisory LLC raised its position in Eli Lilly and Company by 17.8% in the second quarter. GoalVest Advisory LLC now owns 1,479 shares of the company’s stock valued at $1,153,000 after purchasing an additional 224 shares during the period. Wesleyan Assurance Society raised its position in Eli Lilly and Company by 320.0% in the second quarter. Wesleyan Assurance Society now owns 10,500 shares of the company’s stock valued at $8,180,000 after purchasing an additional 8,000 shares during the period. Finally, Pasadena Private Wealth LLC raised its position in Eli Lilly and Company by 206.6% in the second quarter. Pasadena Private Wealth LLC now owns 2,410 shares of the company’s stock valued at $1,878,000 after purchasing an additional 1,624 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity

In related news, CEO David A. Ricks bought 1,632 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock worth $2,894,841 over the last three months. Company insiders own 0.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on LLY. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. BMO Capital Markets lifted their target price on Eli Lilly and Company from $840.00 to $930.00 and gave the company an “outperform” rating in a research report on Monday, October 20th. UBS Group reduced their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reduced their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Finally, Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $938.61.

Eli Lilly and Company Price Performance

LLY stock opened at $825.74 on Tuesday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a market capitalization of $781.53 billion, a PE ratio of 53.97, a P/E/G ratio of 1.23 and a beta of 0.47. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $935.63. The business’s fifty day moving average price is $770.54 and its 200 day moving average price is $769.08.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.